Digoxin (Digitek)
3024
relevant articles (237 outcomes,
396 trials/studies)
found for this Drug
Description:
A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
Also Known As:
Digitek; Lanoxicaps; Lanoxin; AWD.pharma Brand of Digoxin; Bertek Brand of Digoxin; Digacin; Digoregen; Digoxina Boehringer; Digoxine Nativelle; Dilanacin; Glaxo Wellcome Brand of Digoxin; GlaxoSmithKline Brand 1 of Digoxin; GlaxoSmithKline Brand 2 of Digoxin; Hemigoxine Nativelle; Kern Brand of Digoxin; Lanacordin; Lanicor; Lanoxin-PG; Lenoxin; Lilly Brand of Digoxin; Mapluxin; Novartis Brand of Digoxin; Proctor & Gamble Brand of Digoxin; R.A.N. Brand of Digoxin; Roche Brand of Digoxin; Teofarma Brand of Digoxin; UDL Brand of Digoxin; Virco Brand of Digoxin; Boehringer, Digoxina; Lanoxin PG; Nativelle, Digoxine; Nativelle, Hemigoxine; Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-
Relationship Network
Drug Context: Research Results